Liraglutide
Weight Management, Type 2 Diabetes & GLP-1 Metabolic Science
STRONG HUMAN EVIDENCE
FDA-APPROVED
APPROVED FOR SPECIFIC INDICATIONS
What Is Liraglutide?
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist designed to mimic the biological activity of naturally occurring human GLP-1.
It is approximately 97% similar in amino-acid sequence to native human GLP-1. Unlike natural GLP-1, which is rapidly broken down in the body, liraglutide has been modified to resist degradation and has an approximately 13-hour plasma half-life, allowing once-daily administration.
GLP-1 receptors participate in several metabolic processes. Liraglutide can reduce appetite and calorie intake, increase glucose-dependent insulin secretion, reduce glucagon secretion, delay gastric emptying, and improve blood-glucose regulation. FDA labeling states that liraglutide reduces body weight primarily through decreased calorie intake rather than increased energy expenditure.
Liraglutide has been FDA-approved since 2010 and has a substantially stronger human evidence base than many experimental peptides discussed in metabolic and wellness medicine.
Important: The FDA-approved indication depends on the product, dose, and patient population. Approval of liraglutide does not extend to every formulation, compounded product, or proposed use.
Why Are Researchers Interested?
Research interest in liraglutide centers primarily on its effects on the GLP-1 metabolic pathway. Scientists have studied liraglutide extensively for:
Unlike many investigational peptides, liraglutide has been evaluated in large randomized clinical trials involving thousands of people.
What The Research Suggests
Liraglutide Produces Clinically Meaningful Weight Loss
One of the landmark liraglutide weight-management trials was the SCALE Obesity and Prediabetes trial, involving 3,731 adults without diabetes who had obesity or overweight with qualifying health conditions. After 56 weeks, liraglutide 3.0 mg produced an average weight loss of approximately 8.4 kg compared with approximately 2.8 kg for placebo.
In addition, 63.2% of liraglutide-treated participants lost at least 5% of their body weight compared with 27.1% receiving placebo, and 33.1% lost more than 10% compared with 10.6% receiving placebo. This provides strong human evidence supporting liraglutide as a chronic weight-management medication.
Weight Management Is an FDA-Approved Use
Current FDA-approved labeling for Saxenda® indicates liraglutide, together with a reduced-calorie diet and increased physical activity, for long-term weight reduction and maintenance in adults with obesity, adults with overweight plus at least one weight-related medical condition, and pediatric patients age 12 years and older weighing more than 60 kg with obesity.
The recommended maintenance dose for Saxenda is 3 mg once daily. This means that, unlike many experimental “fat-loss peptides,” liraglutide's role in weight management is supported by both large human clinical trials and FDA approval.
Liraglutide Has Strong Evidence for Type 2 Diabetes
Liraglutide is also FDA-approved under the brand name Victoza®. Current labeling indicates Victoza as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes and pediatric patients age 10 and older with type 2 diabetes.
Liraglutide stimulates insulin secretion and suppresses glucagon in a glucose-dependent manner, helping lower blood glucose. The glucose-dependent nature of this activity is important because its insulin-stimulating effect becomes greater when glucose levels are elevated.
Cardiovascular Benefits Have Been Demonstrated in a Specific Population
One of liraglutide's most important clinical trials was LEADER, involving 9,340 adults with type 2 diabetes and high cardiovascular risk. Participants were followed for a median of 3.8 years.
The primary cardiovascular outcome — cardiovascular death, nonfatal heart attack, or nonfatal stroke — occurred in 13.0% receiving liraglutide versus 14.9% receiving placebo. Cardiovascular death occurred in 4.7% receiving liraglutide versus 6.0% receiving placebo.
As a result, Victoza's current FDA label includes an indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. This cardiovascular evidence should be kept population-specific. It does not mean liraglutide has been proven to prevent cardiovascular disease in every person taking it for weight loss.
Long-Term Prediabetes Research Is Encouraging
Researchers have also studied liraglutide in people with obesity and prediabetes. A three-year extension of the SCALE program followed participants for 160 weeks.
During treatment, type 2 diabetes was diagnosed in approximately 2% of liraglutide-treated participants versus 6% receiving placebo. The calculated time to diabetes diagnosis was approximately 2.7 times longer with liraglutide than placebo. At 160 weeks, average weight change was −6.1% with liraglutide versus −1.9% with placebo.
This provides important evidence concerning diabetes risk in the studied population. However, liraglutide does not have a separate FDA indication specifically labeled as “diabetes prevention.”
Liraglutide Can Help Maintain Weight Loss
Weight maintenance has also been studied. In the SCALE Maintenance trial, participants first lost at least 5% of their body weight through a low-calorie diet and were then randomized to liraglutide or placebo.
Liraglutide helped participants maintain previous weight loss and achieve additional weight reduction compared with placebo. This supports the concept of obesity as a chronic condition requiring ongoing management, rather than simply a short-term dieting problem.
Evidence At A Glance
Chronic Weight Management
Large randomized human trials demonstrate clinically meaningful weight reduction in people with obesity or qualifying overweight.
Type 2 Diabetes
Victoza is FDA-approved to improve glycemic control in adults and children age 10 and older with type 2 diabetes.
Cardiovascular Risk Reduction
Victoza is approved to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Prediabetes / Diabetes Prevention
Three-year research demonstrated delayed progression to type 2 diabetes in participants with obesity and prediabetes, but this is not a separate FDA-approved indication.
Weight-Loss Maintenance
Randomized studies demonstrate that liraglutide can help maintain previously achieved weight loss.
Anti-Aging / Longevity
No FDA-approved longevity or anti-aging indication exists.
Safety & Limitations
Liraglutide has been studied much more extensively than experimental peptides, but it still has meaningful safety considerations. The current FDA-approved Saxenda labeling contains a boxed warning concerning thyroid C-cell tumors. Liraglutide caused thyroid C-cell tumors in rats and mice; whether liraglutide causes medullary thyroid carcinoma in humans remains unknown. Saxenda and Victoza are contraindicated in people with a personal history of medullary thyroid carcinoma, a family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Gastrointestinal Effects
The most common adverse reactions with weight-management liraglutide include nausea, diarrhea, constipation, vomiting, abdominal discomfort, dyspepsia, headache, fatigue, dizziness, and injection-site reactions. Current FDA labeling states that liraglutide is not recommended in patients with severe gastroparesis.
Pancreatitis
Acute pancreatitis has been observed with GLP-1 receptor agonists, including liraglutide. FDA labeling recommends discontinuing the medication if pancreatitis is suspected and obtaining appropriate medical evaluation.
Gallbladder Disease
Liraglutide treatment has been associated with gallstones and gallbladder inflammation. FDA recommends appropriate gallbladder evaluation when these conditions are suspected.
Kidney Injury From Dehydration
Severe nausea, vomiting, or diarrhea can cause volume depletion. FDA warns that acute kidney injury may occur secondary to dehydration and recommends monitoring renal function when significant volume-loss symptoms occur.
Hypoglycemia
Liraglutide can increase the risk of hypoglycemia when combined with medications that lower blood glucose, particularly insulin and sulfonylureas or other insulin secretagogues. Dose adjustment of those medications may sometimes be necessary under medical supervision.
Heart Rate
Liraglutide can increase resting heart rate. Current Saxenda labeling recommends monitoring heart rate periodically during treatment.
Pregnancy
Current FDA labeling states that liraglutide used for weight management may cause fetal harm and should be discontinued when pregnancy is recognized.
Surgery and Sedation
Because GLP-1 receptor agonists delay gastric emptying, FDA labeling includes a warning regarding pulmonary aspiration during general anesthesia or deep sedation. Patients should tell their healthcare providers that they are taking liraglutide before planned procedures requiring anesthesia or deep sedation.
Regulatory Status
Yes. Liraglutide has several FDA-approved uses depending upon the product and dose.
Saxenda® is FDA-approved, along with a reduced-calorie diet and increased physical activity, for chronic weight management in adults with obesity, adults with overweight and at least one weight-related comorbidity, and adolescents age 12 and older with obesity who meet the weight requirement.
Victoza® is FDA-approved for improving glycemic control in adults and pediatric patients age 10 and older with type 2 diabetes, and for reducing major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
FDA-Approved Liraglutide vs. Compounded Liraglutide
FDA-approved liraglutide products have undergone review for drug identity, manufacturing, potency, purity, stability, safety, effectiveness, and labeling. FDA-approved prescription products include formulations used for diabetes and chronic weight management.
A compounded liraglutide product is not itself an FDA-approved drug product. Compounded medications do not undergo the same premarket FDA review for safety, effectiveness, and manufacturing quality that approved products undergo.
This distinction is especially important now. On April 30, 2026, FDA announced a proposal to exclude liraglutide, semaglutide, and tirzepatide from the 503B Bulks List, stating that it had not identified a clinical need for outsourcing facilities to compound these drugs from bulk drug substances. That action was a proposal, not itself a statement that all patient-specific compounding of liraglutide is prohibited. Compounding remains governed by the applicable 503A or 503B requirements and other federal and state law.
Regulatory Status: FDA-Approved for Specific Indications — Liraglutide is FDA-approved for specific indications including chronic weight management and type 2 diabetes. Certain liraglutide products are also approved to reduce cardiovascular risk in qualifying adults with type 2 diabetes. FDA approval of liraglutide does not mean that every formulation, compounded product, dose, or proposed use is FDA-approved. Future regulatory status cannot be predicted.
Saxenda® vs. Victoza®
Saxenda and Victoza contain the same active molecule, but they have different FDA-approved indications and dosing frameworks. Evidence from one indication should therefore be presented in its proper clinical context.
Saxenda®
Active Ingredient: Liraglutide. Primary purpose: Chronic weight management. Typical approved maintenance dose: 3 mg once daily.
Victoza®
Active Ingredient: Liraglutide. Primary purpose: Type 2 diabetes. It also has an FDA-approved cardiovascular-risk-reduction indication for qualifying adults with type 2 diabetes and established cardiovascular disease.
Compounded Liraglutide
A compounded liraglutide product is not an FDA-approved drug product. Clinical evidence obtained with FDA-approved liraglutide products should not automatically be used to claim that an independently compounded formulation has identical potency, purity, stability, sterility, absorption, safety, or effectiveness.
Why the Difference Matters: These medications contain the same active drug, but their FDA-approved labeling and indications differ. A compounded formulation is not an FDA-approved drug product, and clinical-trial evidence involving FDA-reviewed liraglutide should not automatically be applied to compounded versions.
Research & Publications
Current FDA Prescribing Information — Saxenda
DailyMed / U.S. FDA Label — Revised 2026
Current prescribing information covering chronic weight management, pediatric use, contraindications, boxed warning, safety information, pharmacology, and clinical studies.
View Current Saxenda Prescribing InformationCurrent FDA Prescribing Information — Victoza
DailyMed / U.S. FDA Label — Current Label
Current prescribing information covering type 2 diabetes, pediatric use, and reduction of major cardiovascular events in qualifying adults.
View Current Victoza Prescribing InformationSCALE Obesity and Prediabetes — Liraglutide for Weight Management
New England Journal of Medicine — 2015
A randomized controlled trial involving more than 3,700 adults demonstrated greater weight loss with liraglutide 3 mg than placebo over 56 weeks.
View SCALE Weight-Management Trial on PubMedThree-Year SCALE Obesity & Prediabetes Trial
The Lancet — 2017
Long-term randomized research evaluating weight management and progression from prediabetes to type 2 diabetes during 160 weeks of liraglutide therapy.
View 3-Year SCALE Study on PubMedLEADER — Cardiovascular Outcomes With Liraglutide
New England Journal of Medicine — 2016
A major cardiovascular-outcomes trial involving 9,340 people with type 2 diabetes and high cardiovascular risk. Liraglutide significantly reduced the study's primary composite cardiovascular endpoint compared with placebo.
View LEADER Trial on PubMedSCALE Maintenance Trial
International Journal of Obesity — 2013
Randomized research examining whether liraglutide could help maintain and extend weight loss initially achieved through a low-calorie diet.
View SCALE Maintenance Study on PubMedSCALE Insulin Trial
Diabetes Care — 2020
A randomized controlled study in people with overweight or obesity and insulin-treated type 2 diabetes. Liraglutide 3 mg produced greater weight reduction than placebo while also improving glycemic measures.
View SCALE Insulin Trial on PubMedFDA — Liraglutide and the 503B Bulks List
U.S. Food and Drug Administration — April 30, 2026
FDA proposed excluding liraglutide, semaglutide, and tirzepatide from the 503B Bulks List after concluding that it had not identified a clinical need for outsourcing facilities to compound them from bulk drug substances.
View FDA 503B Liraglutide AnnouncementLiraglutide has a substantial human clinical evidence base and multiple FDA-approved medical uses. Large randomized clinical trials support its role in chronic weight management and type 2 diabetes, and cardiovascular-outcomes research has demonstrated additional benefit in a specific population of adults with type 2 diabetes and established cardiovascular disease.
Long-term studies have also examined prediabetes and diabetes progression, but those findings should be distinguished from separately FDA-approved indications. FDA approval of liraglutide products should also not be interpreted as FDA approval of every compounded formulation or proposed use of liraglutide.
Liraglutide's established metabolic benefits should likewise not be extended into unsupported claims involving permanent metabolic resetting, anti-aging, or lifespan extension. This page is provided for educational purposes only. Liraglutide is not offered for sale, prescription, or distribution through this website.